On October 15, 2020 BioInvent International AB ("BioInvent") (OMXS: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, and Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, reported that they will be presenting a poster on BT-001 at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 35th Anniversary Annual Meeting (Press release, BioInvent, OCT 15, 2020, View Source [SID1234568494]). The congress will be held virtually from November 9 to14, 2020.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

BT-001 is an optimized oncolytic virus (OV) being co-developed by BioInvent and Transgene.

Title of abstract: BT-001, an oncolytic vaccinia virus armed with a Treg-depleting human recombinant anti-CTLA4 antibody and GM-CSF to target the tumor microenvironment

Authors: Monika Semmrich, Jean-Baptiste Marchand, Laetitia Fend, Matilda Rehn, Nathalie Silvestre, Linda Mårtensson, Johann Foloppe, Ingrid Teige, Eric Quéméneur and Björn Frendeus

Abstract number: 594

The poster will be available in the Virtual Poster Hall November 11-14, 2020, 9:00 a.m. – 5:00 p.m. EST (3:00 – 11:00 p.m. CET). The presenting authors will answer questions on Thursday, November 12 from 4:50 to 5:20 p.m. EST (10:50 – 11:20 p.m. CET) and Saturday, November 14 from 1 to 1:30 p.m. EST (7:00 – 7:30 p.m. CET).

On October 15, 2020 OncoPep, Inc. reported a licensing agreement with MANA Therapeutics for use of its EDIFY platform for the development of an autologous multi-tumor antigen adoptive T cell therapy for the treatment of multiple myeloma and solid tumors, as an additional T cell focused immunotherapeutic for its product pipeline (Press release, OncoPep, OCT 15, 2020, View Source [SID1234568493]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The addition of a multi-antigen adoptive T cell therapy to our pipeline expands the breadth of our immuno-oncology programs in multiple myeloma in addition to solid tumors, and provides patients with another potential treatment option for a disease for which there is no cure," said Doris Peterkin, Chief Executive Officer of OncoPep. "Our initial focus will be developing this unique adoptive T cell therapy for the potential treatment of patients with multiple myeloma."

OncoPep is developing the adoptive T cell therapy as part of a licensing agreement with MANA Therapeutics. MANA’s EDIFY platform is specifically designed to train T cells to target multiple tumor associated antigens, harnessing the patient’s immune system for an approach that targets a broader set of antigens expressed by the tumor. In this collaboration, a patient’s T cells will be trained ex vivo with EDIFY to target the antigens, XBP1, CD138 and CS1, which are highly over-expressed in multiple myeloma and other solid tumors. OncoPep’s lead therapeutic cancer vaccine candidate, PVX-410, is also designed to train T cells to target XBP1, CD138 and CS1 and could potentially be used in combination with the adoptive T cell therapy. This new adoptive T cell therapy approach has the potential to provide more persistent and durable control over tumor cell growth and could prevent the progression of cancer and improve quality of life for patients with multiple myeloma.

"The OncoPep team has developed a deep scientific understanding of multiple myeloma and the complexities of the disease," said Martin Silverstein, M.D., President and Chief Executive Officer of MANA Therapeutics. "MANA’s EDIFY platform has already been studied in two clinical trials using ManaMix antigens, and is being deployed in additional clinical trials under MANA’s INDs. We are pleased to enter into a licensing agreement with OncoPep that will expand the application of our EDIFY platform to a new set of tumor antigens that are over-expressed in multiple myeloma and specified solid tumors."

About Multiple Myeloma

Multiple myeloma (MM) is a debilitating type of hematologic cancer that affects plasma cells. It is the second most common blood cancer, accounting for 13% of all hematologic cancers and 1% of all cancer deaths. MM is characterized by a proliferation of malignant plasma cells, which may in turn interfere with the normal production of blood cells. MM causes significant side effects, such as debilitating bone pain and fractures, anemia, leukopenia, thrombocytopenia, renal insufficiency and failure, hypercalcemia and increased chance of infection.

On October 14, 2020 BioCure Technology Inc. (CSE: CURE) ("BioCure" or the "Company") reported that it will close a non-brokered private placement (the "Private Placement" on October 15th, 2020 consisting of 1,786,725 Units at a price of $0.14 cents per Unit for gross proceeds of $250,142 (Press release, Biocure Technology, OCT 14, 2020, View Source [SID1234628751]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Each Unit is comprised of one common share (the "Shares) and one share purchase warrant (the "Warrants") of the Company, where each whole Warrant entitles the holder to purchase an additional share for a period of two years from closing at a price of $0.21 per Warrant share (the "Warrant Shares").

The Company also agreed to pay a finder’s fee of $3,360 ("Finders Cash") and 24,000 finder warrants ("Finder Warrants") for the proceeds raised by the finders ("Finders") in connection with the private placement. The Finder Warrants are exercisable for a period of one year from closing at a price of $0.21 per share.

The net proceeds from the non-brokered private placement are intended to be used for general working capital and research and development.
All securities issuance in the Private Placement will be subject to a hold period expiring on February 15, 2021.

On October 14, 2020 Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage company focused on making a positive impact on patients’ lives, reported that the company will report 2020 third quarter financial results on Thursday, October 22, 2020, after market close (Press release, PLUS THERAPEUTICS, OCT 14, 2020, View Source [SID1234572292]). Subsequently, Plus Therapeutics’ management team will host a conference call and webcast at 5:00 p.m. Eastern Time to discuss the financial results and provide a corporate update.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast will be available at ir.plustherapeutics.com/events

Please refer to the information below for conference call dial-in information. Callers should dial in approximately 10 minutes prior to the start of the call.

Conference Call Name: Plus Therapeutics Third Quarter 2020 Financial Results Conference Call
Following the live call, a replay will be available on the Company’s website under the ‘Investors Relations’ section. The webcast will be available on the Company’s website for 90 days following the live call.

On October 14, 2020, Sorrento Therapeutics, Inc. ("Sorrento") and ACEA Therapeutics, Inc. ("ACEA") reported that entered into a binding term sheet (the "Binding Term Sheet") setting forth the terms and conditions by which Sorrento will, through a subsidiary, purchase all of the issued and outstanding equity of ACEA (the "Acquisition") (Filing, 8-K, Sorrento Therapeutics, OCT 14, 2020, View Source [SID1234568573]). Contingent upon the execution of a definitive agreement between the parties (the "Definitive Agreement") and subject to certain conditions, Sorrento will, at the closing of the Acquisition (the "Closing"), make an initial payment of $38,000,000, subject to certain adjustments (the "Initial Consideration").

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In addition to the Initial Consideration, Sorrento shall issue contingent value rights to the equityholders of ACEA representing the right to receive the following payments: (i) the amounts that would otherwise be due to ACEA under that certain License Agreement, dated July 13, 2020 (the "License Agreement"), between Sorrento and ACEA (as previously disclosed in Sorrento’s Current Report on Form 8-K filed with the Securities and Exchange Commission on July 17, 2020), (ii) with respect to specified royalty-bearing products, five percent of the annual net sales thereof in a manner consistent with the royalty payment terms of the License Agreement, and (iii) up to $265,000,000 in additional payments, subject to the receipt of certain regulatory approvals and achievement of certain net sales targets with respect to the assets acquired pursuant to the Acquisition.

Under the Binding Term Sheet, ACEA has agreed to negotiate exclusively with Sorrento with respect to the Acquisition for a period of 90 days.

The final terms of the Acquisition are subject to the negotiation and finalization of the Definitive Agreement and any other agreements relating to the Acquisition, and the material terms of the Acquisition may differ from those set forth in the Binding Term Sheet. In addition, the Closing will be subject to various customary and other closing conditions, including the approval of ACEA’s equityholders.

The foregoing description of terms of the Binding Term Sheet does not purport to be complete and is qualified in its entirety by reference to the full text of the (i) Binding Term Sheet that will be filed with the Securities and Exchange Commission as an exhibit to an amendment to this Current Report on Form 8-K or to Sorrento’s Annual Report on Form 10-K for the fiscal year ending December 31, 2020, and (ii) the License Agreement that will be filed with the Securities and Exchange Commission as an exhibit to Sorrento’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2020.